Changeflow GovPing Healthcare & Life Sciences Legend Biotech CD33 Single-Domain Antibodies EP...
Routine Rule Added Final

Legend Biotech CD33 Single-Domain Antibodies EP3850011A1

Favicon for changeflow.com EPO Patent Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

The European Patent Office published patent application EP3850011A1 for single-domain antibodies targeting CD33, filed by Legend Biotech Ireland Limited and Legend Biotech USA Inc. The application covers antibodies for potential therapeutic use in cancer treatment, with six named inventors: ZHANG Yafeng, ZHAN Tailan, SUN Fei, LIU Jian, ZHANG Qing, and WU Shu. The patent is classified under IPC categories A61K, A61P, and C07K.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 46 changes logged to date.

What changed

The EPO published patent application EP3850011A1, a single-domain antibody construct targeting CD33 filed by Legend Biotech Ireland Limited and Legend Biotech USA Inc. The application covers therapeutic uses for cancer treatment as indicated by IPC classifications A61K 39/395 and A61P 35/00.

Pharmaceutical and biotechnology companies developing CD33-targeted therapies or related immunological constructs should review this publication for potential freedom-to-operate implications. The patent designates 27 European Patent Convention member states, creating IP protection scope across major European markets.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

SINGLE-DOMAIN ANTIBODIES AGAINST CD33 AND CONSTRUCTS THEREOF

Publication EP3850011A1 Kind: A1 Apr 15, 2026

Applicants

Legend Biotech Ireland Limited, Legend Biotech USA Inc.

Inventors

ZHANG, Yafeng, ZHAN, Tailan, SUN, Fei, LIU, Jian, ZHANG, Qing, WU, Shu

IPC Classifications

A61K 39/395 20060101AFI20220912BHEP A61P 35/00 20060101ALI20220912BHEP C07K 16/28 20060101ALI20220912BHEP C07K 19/00 20060101ALI20220912BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254.1 Biotechnology
Activity scope
Patent examination IP licensing
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!